B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

PHASE4RecruitingINTERVENTIONAL

Enrollment

296

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

March 31, 2026

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Ocrelizumab

Personalized B cell tailored ocrelizumab treatment

Trial Locations (1)

RECRUITING

Amsterdam UMC, location VU, Amsterdam

All Listed Sponsors

lead

Amsterdam UMC, location VUmc

OTHER